| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
While examples of all oxadiazole isomers have been identified, biotransformation pathways for compounds containing a 1,2,4-oxadiazole ring have been reported to date. (A15200) |
|---|---|
| Toxicity/Toxicokinetics |
Toxicity Summary
"Oxadiazole belongs to the oxadiazole class of herbicides. Although current data is limited, the U.S. Environmental Protection Agency (EPA) has evidence that compounds in the same class may share common toxicity mechanisms. Currently, the EPA does not have sufficient data to determine whether oxadiazole shares common toxicity mechanisms with other substances, including other oxadiazole compounds or other possible human carcinogens." (L2081) Toxicity Data LC50 (Rats) > 200,000 mg/m3 LD50 > 5000 mg/kg (oral, rat) (L2081); LD50 > 2000 mg/kg (dermal, rabbit) (L2081); LC50 > 1.94 mg/L (inhalation, rat) (L2081) Non-human Toxicity Values LD50 (Rats, oral (acute)) > 3,500 mg/kg LD50 (Rats, oral) > 5000 mg/kg LD50 (rat, transdermal) >2000 mg/kg |
| Additional Infomation |
According to an independent committee of scientific and health experts, oxazolidinone may be carcinogenic. According to the U.S. Environmental Protection Agency (EPA), it may have developmental toxicity. Oxazolidinone is a crystalline solid used as a herbicide. Oxazolidinone is an aromatic ether. Oxazolidinone can be used as a pre-emergence and post-emergence herbicide. It is primarily used on cotton, rice, soybeans, and sunflowers, and its mechanism of action is the inhibition of protoporphyrinogen oxidase (PPO).
|
| Molecular Formula |
C15H18CL2N2O3
|
|---|---|
| Molecular Weight |
345.22
|
| Exact Mass |
344.069
|
| CAS # |
19666-30-9
|
| PubChem CID |
29732
|
| Appearance |
White crystals
Colorless crystals |
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
417.0±55.0 °C at 760 mmHg
|
| Melting Point |
88-90°C
|
| Flash Point |
206.0±31.5 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.569
|
| LogP |
4.55
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
462
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1OC(C(C)(C)C)=NN1C2=CC(OC(C)C)=C(Cl)C=C2Cl
|
| InChi Key |
CHNUNORXWHYHNE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H18Cl2N2O3/c1-8(2)21-12-7-11(9(16)6-10(12)17)19-14(20)22-13(18-19)15(3,4)5/h6-8H,1-5H3
|
| Chemical Name |
5-tert-butyl-3-(2,4-dichloro-5-propan-2-yloxyphenyl)-1,3,4-oxadiazol-2-one
|
| Synonyms |
G-315; G 315; Oxadiazon
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~144.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.24 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.24 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.24 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8967 mL | 14.4835 mL | 28.9670 mL | |
| 5 mM | 0.5793 mL | 2.8967 mL | 5.7934 mL | |
| 10 mM | 0.2897 mL | 1.4484 mL | 2.8967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
